Abstract
Surgery alone is no longer appropriate to the treatment of T3-T4 resecable rectal cancer. Preoperative chemoradiotherapy has recently been approved as the new standard treatment. This approach improves local control with local failure rate raranging now around 6-8%. However, it does not impact on overall survival. It becomes urgent to develop new concepts and a basic research in the understanding of the biological mechanisms that may explain the resistance of the micrometastatic process.
MeSH terms
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / therapeutic use
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Combined Modality Therapy
-
Drug Therapy, Combination
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / therapeutic use
-
Humans
-
Leucovorin / administration & dosage
-
Leucovorin / therapeutic use
-
Male
-
Neoplasm Metastasis
-
Neoplasm Recurrence, Local / prevention & control
-
Neoplasm Staging
-
Preoperative Care
-
Prognosis
-
Radiotherapy Dosage
-
Randomized Controlled Trials as Topic
-
Rectal Neoplasms / diagnostic imaging
-
Rectal Neoplasms / drug therapy*
-
Rectal Neoplasms / mortality
-
Rectal Neoplasms / pathology
-
Rectal Neoplasms / radiotherapy*
-
Rectal Neoplasms / surgery*
-
Rectum / pathology
-
Tomography, X-Ray Computed
-
Vitamin B Complex / administration & dosage
-
Vitamin B Complex / therapeutic use
Substances
-
Antimetabolites, Antineoplastic
-
Vitamin B Complex
-
Leucovorin
-
Fluorouracil